Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | LIG1 | P18858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121031 | 0.88 | FLT3 (0.47) | TSHRGAAFLT3LIG1KDM4E | |
| SCHEMBL3319882 | 0.88 | GAA (0.68) | TSHRGAAFLT3LIG1TP53 | |
| SCHEMBL2374331 | 0.85 | HSP90AA1 (0.50) | TSHRGAAFLT3LIG1KDM4E | |
| SCHEMBL27347230 | 0.84 | GAA (0.46) | TSHRGAAFLT3LIG1KDM4E | |
| SCHEMBL2902590 | 0.83 | FLT3 (0.66) | TSHRGAAFLT3KDM4EALDH1A1 | |
| SCHEMBL28948144 | 0.83 | MAOB (0.49) | TSHRGAAKDM4EALDH1A1TDP1 | |
| SCHEMBL7635214 | 0.83 | TSHR (0.57) | TSHRGAAFLT3LIG1TP53 | |
| SCHEMBL15007788 | 0.81 | FLT3 (0.43) | TSHRGAAFLT3LIG1KDM4E | |
| SCHEMBL8168167 | 0.81 | TSHR (0.68) | TSHRGAAFLT3LIG1TP53 | |
| SCHEMBL20471839 | 0.81 | TSHR (0.56) | TSHRGAAFLT3LIG1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920413-B1 | BORONIC COMPOUND COMPLEXING REAGENTS AND COMPLEXES | PROLINX INC (US) | 2002-11-13 | — | — | EP | claimed |
| US-20240027903-A1 | Resist Material And Patterning Process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-0231139-A2 | Dihydrobenzofurane and chromane carboxamide derivatives, processes for their preparation and their use as neuroleptics | Laboratoires DELAGRANGE (FR) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | TSHR 2806/4885GAA 4826/4885FLT3 4473/4885 |
| US-20240027903-A1 | Resist Material And Patterning Process | LBR, HNRNPU, EWSR1 | TSHR 2364/4885GAA 3050/4885FLT3 3598/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | TSHR 2862/4885GAA 4826/4885FLT3 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.